Literature DB >> 16648405

Trends in the incidence of invasive and in situ vulvar carcinoma.

Patricia L Judson1, Elizabeth B Habermann, Nancy N Baxter, Sara B Durham, Beth A Virnig.   

Abstract

OBJECTIVE: To characterize the incidence of vulvar carcinoma in situ and vulvar cancer over time.
METHODS: We used the Surveillance Epidemiology and End Results database to assess trends in the incidence of vulvar cancer over a 28-year period (1973 through 2000) and determined whether there had been a change in incidence over time. Information collected included patient characteristics, primary tumor site, tumor grade, and follow-up for vital status. We calculated the incidence rates by decade of age, used chi(2) tests to compare demographic characteristics, and tested for trends in incidence over time.
RESULTS: A total of 13,176 in situ and invasive vulvar carcinomas were identified; 57% of the women were diagnosed with in situ, 44% with invasive disease. Vulvar carcinoma in situ increased 411% from 1973 to 2000. Invasive vulvar cancer increased 20% during the same period. The incidence rates for in situ and invasive vulvar carcinomas are distributed differently across the age groups. In situ carcinoma incidence increases until the age of 40-49 years and then decreases, whereas invasive vulvar cancer risk increases as a woman ages, increasing more quickly after 50 years of age.
CONCLUSION: The incidence of in situ vulvar carcinoma is increasing. The incidence of invasive vulvar cancer is also increasing but at a much lower rate.

Entities:  

Mesh:

Year:  2006        PMID: 16648405     DOI: 10.1097/01.AOG.0000210268.57527.a1

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  77 in total

1.  [The female external genitalia : pathologic findings and first steps in treatment].

Authors:  C Goldnau; A Köninger; R Kimmig
Journal:  Urologe A       Date:  2010-12       Impact factor: 0.639

Review 2.  Vulvar cancer: a review for dermatologists.

Authors:  Anastasiya Atanasova Chokoeva; Georgi Tchernev; Elena Castelli; Elisabetta Orlando; Shyam B Verma; Markus Grebe; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2015-05-01

Review 3.  Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines.

Authors:  Tommy R Buchanan; Whitney S Graybill; Jennifer Young Pierce
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Successful implementation and results of an HPV vaccination program in Geneva Canton, Switzerland.

Authors:  Emilien Jeannot; Patrick Petignat; Philippe Sudre
Journal:  Public Health Rep       Date:  2015 May-Jun       Impact factor: 2.792

5.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

Review 6.  Advanced Vulvar Cancers: What are the Best Options for Treatment?

Authors:  Alejandro Soderini; Alejandro Aragona; Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

7.  Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients.

Authors:  Kruti P Maniar; Brigitte M Ronnett; Russell Vang; Anna Yemelyanova
Journal:  Am J Surg Pathol       Date:  2013-01       Impact factor: 6.394

8.  Human papillomavirus-related gynecologic neoplasms: screening and prevention.

Authors:  Whitfield B Growdon; Marcela Del Carmen
Journal:  Rev Obstet Gynecol       Date:  2008

9.  Vulvar Intraepithelial Neoplasia 3 in Women Less Than 35 Years.

Authors:  Joshua P Kesterson; Shashikant Lele
Journal:  J Low Genit Tract Dis       Date:  2009-10       Impact factor: 1.925

Review 10.  HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women.

Authors:  Maura L Gillison; Anil K Chaturvedi; Douglas R Lowy
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.